Eyedaptic reports immediate vision gains in retinal disease study

Eyedaptic said an independent clinical evaluation presented at the American Retina Forum found immediate functional vision improvements in patients with advanced retinal disease after fitting the company’s wearable device. The results, including average near-vision gains of 5.7 lines, suggest wearable visual enhancement could complement retinal care for people with irreversible central vision loss.

Why it matters: - Patients with advanced retinal disease often still struggle with reading, recognizing faces and working even after medical treatment. - Eyedaptic’s wearable technology is designed to improve functional vision in real time, not slow disease progression. - The new results suggest wearable visual enhancement could add a practical layer to retinal care for people whose needs remain unmet by current therapies.

What happened: - Eyedaptic announced positive results from an independent real-world clinical evaluation presented by David Almeida, MD, MBA, PhD, FRCSC, at the American Retina Forum Annual Meeting on August 6. - The evaluation was conducted independently at Erie Retina Research. - The study involved 19 patients ages 65 to 100 with advanced retinal disease, including age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa and hereditary retinal dystrophies. - Baseline visual acuity for most patients was between 20/200 and 20/800. - Patients were fitted with Eyedaptic’s wearable visual assistive device and showed immediate improvements in near visual acuity.

The details: - Seventeen of 19 patients, or 89%, showed measurable gains after device fitting. - The average improvement across all patients was 5.7 lines, or more than 28 letters, of near visual acuity. - Responding patients improved by an average of 6.4 lines. - More than half of the responders gained six lines or more. - Seven patients reached reading performance equivalent to 20/20 or 20/25 with the device. - Several patients with advanced or end-stage neovascular AMD improved by 8.5 to 10 lines immediately after fitting. - The presentation also cited improved reading ability, better facial recognition and the potential to resume occupational activities. - One patient with retinitis pigmentosa used the device at work as a cashier and showed a six-line improvement in reading acuity. - The evaluation data were collected independently without sponsorship, review or approval from Eyedaptic. - Almeida disclosed no financial interest in Eyedaptic.

Between the lines: - The results point to a shift in retinal care from only preserving vision to also helping patients use the vision they still have. - The study is not a drug or surgery trial. It measures whether a wearable aid can deliver immediate day-to-day benefit. - The findings may strengthen the case for wearable technology as a complement to anti-VEGF drugs, gene therapies and other retinal treatments.

What’s next: - Eyedaptic is positioning its technology as part of comprehensive vision rehabilitation for people with irreversible central vision loss. - The company said wearable technologies could work alongside pharmacologic and surgical care for appropriately selected patients. - The new findings add to evidence supporting augmented vision tools in advanced retinal disease.